Navigation Links
Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results
Date:7/29/2009

CALGARY, July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today announced its financial results for the three and six-month periods ended June 30, 2009.

"Clinical results from our monotherapy and combination clinical trials with REOLYSIN(R) continued to emerge in the second quarter," said Dr. Brad Thompson, President and CEO of Oncolytics. "The results of these trials, and the response and clinical benefit rates as reported by our investigators, reinforce our belief that REOLYSIN has the potential to significantly improve treatment outcomes in patients with a broad range of cancers."

Selected Second Quarter Highlights

    -   Presented updated U.S. Phase II sarcoma trial data at the American
        Society of Clinical Oncology (ASCO) annual meeting. The interim
        results demonstrated that the treatment was well tolerated, with 15
        of 36, or 42% of evaluable patients experiencing stable disease (SD)
        for more than 16 weeks, including five patients who had SD for more
        than 24 weeks. Patient enrolment was completed in May;

    -   Presented a poster at ASCO demonstrating that the combination of
        REOLYSIN and gemcitabine in a U.K. Phase I trial was well tolerated,
        and resulted in disease control for a majority of the patients. Of
        the ten patients evaluable for response, two patients (breast and
        nasopharyngeal) had partial responses (PRs) and/or clinical responses
        and five patients had SD for 4-8 cycles, for a total disease control
        rate (CR (Complete Response)+PR+SD) of 70%;

    -   Presented a poster at ASCO that indicated REOLYSIN was well tolerated
        and demonstrated anti-tumour activity in a U.S. Phase I systemic
        administration monotherapy trial. Of 18
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) aclinical stage ... antibody, HuMab 5B1, will be garnering major attention as ... World Molecular Imaging Congress (WMIC) being held in ... the Department of Radiology at Memorial Sloan Kettering Cancer ... MabVax,s lead antibody as a PET imaging agent and ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) has announced ... - Growth, Trends & Forecasts (2014-2020)" report to ... Sensors market is estimated at $0.20 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Middle East & Africa Biomedical Sensors Market - Growth, ... The Middle East ... $0.84 billion by 2018 at a CAGR of 3.26% ... will bring Biomedical sensors that are adaptable to the ...
(Date:8/31/2015)... , Aug. 31, 2015 /PRNewswire/ - Portage Biotech Inc. ... Exchange: PBT.U), is pleased to announce that its wholly ... its lead candidate, PPL-003, to an Investigational New Drug ... disease and uveitis.  PPL recently completed a study in ... PPL-003 solution achieved highly significant efficacy and a more ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Mexico Biomedical Sensors Market Report 2015-2020 2Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3
... SAN DIEGO, April 28, 2011 Genomatica ... Chemical Corporation , the eighth-largest chemical maker in the world, ... areas of collaboration.  These include: , Study of ... production in Asia :  Mitsubishi and Genomatica ...
... Qteros, Inc., the developer of a unique and highly ... lowest-cost production of cellulosic ethanol, today announced its plans ... of May. Kevin A. Gray, Ph.D., Senior ... deliver an oral presentation at the 33rd Symposium on ...
... The Center for Business Intelligence (CBI), a division of ... Children,s Rare Disease Network and The Global Genes Project for ... 12 - 13, 2011 at the Doubletree Hotel in Washington, ... They affect few people individually, but there are more than ...
Cached Biology Technology:Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia 2Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia 3Qteros Management to Present at Upcoming Conferences in May 2CBI Announces Partnership With Children's Rare Disease Network and The Global Genes Project 2CBI Announces Partnership With Children's Rare Disease Network and The Global Genes Project 3
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... Genome Project at Penn State University, with an ... to Charles Darwin's "abominable mystery:" the inexplicably rapid ... appearance some 140 million years ago. By ... sequences from thirteen strategically selected plant species, the ...
... an important role in the formation of gold nuggets ... in the international journal, Science .. , The ... for Landscape Environments and Mineral Exploration (CRC LEME) project ... has shown that bacteria play a significant role in ...
... Medical School researchers have discovered one way that a ... of chronically infected cystic fibrosis (CF) patients. ... as Pseudomonas aeruginosa (PA) use protein secretion systems to ... author of the study published in the June 9 ...
Cached Biology News:Massive duplication of genes may solve Darwin's 'abominable mystery' about flowering plants 2Massive duplication of genes may solve Darwin's 'abominable mystery' about flowering plants 3Massive duplication of genes may solve Darwin's 'abominable mystery' about flowering plants 4The Midas Bug -- the bacterial alchemy of gold 2Discovery could aid fight against cystic fibrosis infection 2
Mouse monoclonal [SH-A1] to S100 alpha ( Abpromise for all tested applications). entrezGeneID: 6271 SwissProtID: P23297...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: